MicroRNAs: New Powerful Weapons in Personalized Colon Cancer Treatment

سال انتشار: 1396
نوع سند: مقاله کنفرانسی
زبان: انگلیسی
مشاهده: 493

نسخه کامل این مقاله ارائه نشده است و در دسترس نمی باشد

این مقاله در بخشهای موضوعی زیر دسته بندی شده است:

استخراج به نرم افزارهای پژوهشی:

لینک ثابت به این مقاله:

شناسه ملی سند علمی:

IPMCMED02_051

تاریخ نمایه سازی: 29 فروردین 1397

چکیده مقاله:

Introduction and background: Although chemotherapy is an important therapeutic strategy in colon cancer, but resistance to chemotherapy is one of the biggest threats. Recent studies indicate that some molecules like microRNAs (miRNAs) play critical regulatory role in development of drug resistance to colon cancer. MiRNAs are single- stranded non-coding molecules that can regulate mRNA translation. The specific miRNA profile modulates distinctly resistance and sensitivity to chemotherapy drugs, affecting the expression of cancer genes. Here, we highlight the recent advancements in miRNA-associated chemoresistance researches which are the most common and serious obstacle in colon cancer treatment.Methods: In this narrative review, a comprehensive search of PubMed database was performed with the following Mesh term search using keyword: MicroRNA along with keywords: colon cancer and drug resistance. Published data have been included since first finding until August 2017, in the study. The inclusion criteria for the study were: all studies that introduced new MicroRNA associated with chemoresistance and chemosensitivity in colon cancer treatment.Results: The results from 83 papers provide a broad view of miRNAs involved in the response to chemotherapy in colon cancer. Discussion and Conclusion: Numerous studies have revealed novel aspects of various cellular microRNA-regulated networks such as proliferation, cell cycle, survival and cancer-specific metabolism pathways developed chemoresistance involved in colon cancer. Moreover, recent studies have demonstrated that different microRNAs increase tumor chemosensitivity with induce apoptosis and cell cycle arrest and decrease expression of drug efflux pump genes. Thus, these molecules potentially influence the efficacy of popular chemotherapeutic agents such as 5-fluorouracil, paclitaxel, oxaliplatin, irinotecan, doxorubicin, cetuximab in colon cancer.Therefore, cancer-specific miRNAs signatures provide powerful new weapon in the battle against cancer drug resistance based on personalized cancer care. Lastly, in this review we focus on the latest advances related to miRNA that increase resistance or sensitivity to common anticancer drugs and discuss about opportunities and limitation of miRNA applications for precision colon cancer medicine.

نویسندگان

Nazita Tavazohi

Department of Pharmaceutical Biotechnology, School of Pharmacy, Isfahan University of Medical sciences, Isfahan, Iran.

Mina Mirian

Department of Pharmaceutical Biotechnology, School of Pharmacy, Isfahan University of Medical sciences,Isfahan, Iran.

Hamid Mir Mohammad Sadeghi

Department of Pharmaceutical Biotechnology, School of Pharmacy, Isfahan University of Medical sciences, Isfahan, Iran.

Homa Talabaki

Department of Pharmaceutical Biotechnology, School of Pharmacy, Isfahan University of Medical sciences, Isfahan, Iran.